Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nateglinide vs. Acarbose in Chinese Drug-Naive Type 2 Diabetes Patients
NCT01030952Phase 4Completed
- Sponsor
- Novartis
- Start
- Dec 2009
- Primary completion
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of nateglinide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novartis. Primary endpoint: Area Under Curve of 0-4 Hours Postprandial Glucose at 3 weeks. Started Dec 2009; status: completed.
02
Drugs
nateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01030952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01030952.